Name | Vasomera |
---|
Description | Vasomera is a stable long-acting vasoactive intestinal peptide (VIP) agonist. Vasomera acts on the G-protein-coupled VPAC2-receptors. Vasomera can be used for the research of cardiomyopathy associated with dystrophinopathies[1]. |
---|---|
Related Catalog | |
In Vivo | Vasomera (i.v.; 7.5 μg/kg/min; single) improves arterial elastance and ventriculo-arterial coupling and improves indices of diastolic function (i.e., lusitropy) in animals with chronic renoprival hypertension mimicking heart failure with preserved ejection fraction (HFpEF)[1]. Animal Model: Rats[1] Dosage: 7.5 μg/kg Administration: IV, 7.5 μg/kg/min, single Result: Decreased the estimated arterial elastance, improved ventriculo-arterial coupling, reduced filling pressures, accelerated the time-constant of relaxation and improved compliance. |
References |
No Any Chemical & Physical Properties |